Clinical trials: Neuroendocrine Tumor Carcinoid
Neuroendocrine Tumors, Gastrointestinal Neoplasms
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver.
- Conditions
- Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
- Trial name
- NCT02859064
- Testing
- Lanreotide, Y-90 microspheres
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Carcinoid Syndrome, Carcinoid Tumor
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors.
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Trial name
- NCT04993261
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoid Cancer, Neuroendocrine Tumors
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
- Conditions
- Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors
- Trial name
- NCT02174679
- Testing
- 68Ga DOTATATE
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
Life Following Excision of Neuroendocrine Tumors
Neuroendocrine tumors (NETs), often seen as "chronic cancer" present a survival paradox with relatively prolonged patient survival despite active disease.
- Trial name
- LIFENETS (NCT06981455)
- Where
- Canada
- Volunteers
- 246 people
- Sponsor
- Sunnybrook Health Sciences Centre
Small Bowel Carcinoid Tumor
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
This research study is designed to evaluate a type of scan called Ga-68-DOTA-TOC positron emission tomography (PET) scanning as a way of assessing carcinoid tumors.
- Trial name
- NCT03057509
- Testing
- Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers…
- Trial name
- NCT01466036
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and…
- Conditions
- Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
- Trial name
- NCT05263050
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fox Chase Cancer Center
Carcinoid Heart Disease
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of…
- Trial name
- CRUSOE-NETs (NCT03498040)
- Testing
- Study of the occurrence of Carcinoid Heart Disease
- Where
- 19 sites in France
- Volunteers
- 670 people
- Sponsor
- Hospices Civils de Lyon
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse.
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor
- Trial name
- NCT01841736
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 423 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Midgut Carcinoid Tumor, Biliary Stones
Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery.
- Trial name
- TNE-IDC-COLE (NCT04735198)
- Testing
- Primary tumor surgery, Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
- Where
- 6 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitari de Bellvitge
Carcinoid Tumor, Malignant Carcinoid Syndrome
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid…
- Trial name
- RADIANT-2 (NCT00412061)
- Testing
- Octreotide, Everolimus
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 429 people
- Sponsor
- Novartis Pharmaceuticals
Gastrinoma, Glucagonoma
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00084461
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic…
- Trial name
- NCT00017199
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumor, Carcinoid
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems.
- Conditions
- Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
- Trial name
- RegisterNET (NCT02270567)
- Testing
- NETest
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc